利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.035 秒)

    Methods and materials for assessing prostate cancer therapies and compounds
    6.
    发明申请
    Methods and materials for assessing prostate cancer therapies and compounds 有权
    用于评估前列腺癌疗法和化合物的方法和材料

    公开(公告)号：US20070191443A1

    公开(公告)日：2007-08-16

    申请号：US10590445

    申请日：2005-02-23

    申请人： Michael Jung ,  Samedy Ouk ,  Charles Sawyers ,  Charlie Chen ,  Derek Welsbie

    发明人： Michael Jung ,  Samedy Ouk ,  Charles Sawyers ,  Charlie Chen ,  Derek Welsbie

    IPC分类号： A61K31/4166 ,  C07D233/84

    CPC分类号： A61K31/426

    摘要： A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides for the design of novel antiandrogen compounds.

    摘要翻译： 雄激素受体（AR）mRNA的适度（2-5倍）增加是与抗雄激素治疗发展抵抗力的唯一表达变化。 增加的AR水平通过放大来自低水平的残留配体的信号输出并改变对拮抗剂的正常反应来赋予抗雄激素抗性。 本发明提供用于检查新的治疗方式的基于细胞的测定法，并提供新的抗雄激素化合物的设计。

    METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER THERAPIES AND COMPOUNDS
    7.
    发明申请
    METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER THERAPIES AND COMPOUNDS 有权
    用于评估前列腺癌治疗和化合物的方法和材料

    公开(公告)号：US20080090888A2

    公开(公告)日：2008-04-17

    申请号：US10590445

    申请日：2006-08-24

    申请人： Michael Jung ,  Samedy Ouk ,  Charles Sawyers ,  Charlie Chen ,  Derek Welsbie

    发明人： Michael Jung ,  Samedy Ouk ,  Charles Sawyers ,  Charlie Chen ,  Derek Welsbie

    IPC分类号： A61K31/4166 ,  C07D233/84

    CPC分类号： A61K31/426

    摘要： A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides for the design of novel antiandrogen compounds.

    摘要翻译： 雄激素受体（AR）mRNA的适度（2-5倍）增加是与抗雄激素治疗发展抵抗力的唯一表达变化。 增加的AR水平通过放大来自低水平的残留配体的信号输出并改变对拮抗剂的正常反应来赋予抗雄激素抗性。 本发明提供用于检查新的治疗方式的基于细胞的测定法，并提供新的抗雄激素化合物的设计。

    Methods and materials for assessing prostate cancer therapies and compounds
    9.
    发明授权
    Methods and materials for assessing prostate cancer therapies and compounds 有权
    用于评估前列腺癌疗法和化合物的方法和材料

    公开(公告)号：US07718684B2

    公开(公告)日：2010-05-18

    申请号：US10590445

    申请日：2005-02-23

    申请人： Michael E. Jung ,  Samedy Ouk ,  Charles L. Sawyers ,  Charlie D. Chen ,  Derek Welsbie

    发明人： Michael E. Jung ,  Samedy Ouk ,  Charles L. Sawyers ,  Charlie D. Chen ,  Derek Welsbie

    IPC分类号： A01N43/50 ,  C07D293/00 ,  C07D409/00

    CPC分类号： A61K31/426

    摘要： A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides for the design of novel antiandrogen compounds.

    摘要翻译： 雄激素受体（AR）mRNA的适度（2-5倍）增加是与抗雄激素治疗发展抵抗力的唯一表达变化。 增加的AR水平通过放大来自低水平的残留配体的信号输出并改变对拮抗剂的正常反应来赋予抗雄激素抗性。 本发明提供用于检查新的治疗方式的基于细胞的测定法，并提供新的抗雄激素化合物的设计。

    Methods and materials for assessing prostate cancer therapies
    10.
    发明申请
    Methods and materials for assessing prostate cancer therapies 有权
    用于评估前列腺癌疗法的方法和材料

    公开(公告)号：US20070166717A1

    公开(公告)日：2007-07-19

    申请号：US10583280

    申请日：2004-12-16

    申请人： Charles Sawyer ,  Charlie Chen ,  Derek Welsbie

    发明人： Charles Sawyer ,  Charlie Chen ,  Derek Welsbie

    IPC分类号： C12Q1/68 ,  A61K48/00

    CPC分类号： G01N33/57434 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N2333/723 ,  G01N2500/04

    摘要： Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest (2-5 fold) increase in androgen receptor (AR) mRNA was the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides insight toward the design of novel antiandrogens.

    摘要翻译： 使用基于芯片的同基因前列腺癌异种移植模型，我们发现雄激素受体（AR）mRNA的适度（2-5倍）增加是与抗雄激素治疗发展抵抗力的唯一表达变化。 增加的AR水平通过放大来自低水平的残留配体的信号输出并改变对拮抗剂的正常反应来赋予抗雄激素抗性。 本发明提供用于检查新治疗方式的基于细胞的测定法，并提供对新型抗雄激素的设计的洞察。